Clean Room Lessons from FDA’s Compounding Pharmacy Inspections
This article was originally published in The Gold Sheet
Executive Summary
Reacting to last fall’s fungal meningitis crisis, FDA has inspected more than 50 compounding pharmacies this year looking for poor aseptic practices. What it found makes for a sobering training tool on sterility assurance.
You may also be interested in...
NECC Crisis Festered in Ambiguity That Reigns Over Compounding
As FDA, Congress and the courts stumbled, compounding pharmacies such as NECC took advantage of a gray area of the law. Legislators will get another try; one proposed subjecting such pharmacies to cGMP requirements.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.